These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 39221811)

  • 1. Metabolic syndrome traits differentially and cumulatively influence micro- and macrovascular disease risk in patients with MASLD.
    Henney AE; Riley DR; Hydes TJ; Anson M; Ibarburu GH; Zhao SS; Cuthbertson DJ; Alam U
    Liver Int; 2024 Sep; ():. PubMed ID: 39221811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Metabolic Syndrome and Microvascular and Macrovascular Disease in Type 2 Diabetic Mellitus.
    Lee MY; Hsiao PJ; Huang JC; Hsu WH; Chen SC; Shin SJ
    Am J Med Sci; 2018 Apr; 355(4):342-349. PubMed ID: 29661347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum carboxylesterase-1 levels are associated with metabolic dysfunction associated steatotic liver disease and metabolic syndrome in children with obesity.
    Wang H; Wu S; Weng Y; Yang X; Hou L; Liang Y; Wu W; Ying Y; Ye F; Luo X
    Ital J Pediatr; 2024 Sep; 50(1):162. PubMed ID: 39227971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study.
    Solomon A; Negrea MO; Cipăian CR; Boicean A; Mihaila R; Rezi C; Cristinescu BA; Berghea-Neamtu CS; Popa ML; Teodoru M; Stoia O; Neamtu B
    Healthcare (Basel); 2023 Oct; 11(19):. PubMed ID: 37830733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of excluding hyperglycemia from international diabetes federation metabolic syndrome diagnostic criteria on prevalence of the syndrome and its association with microvascular complications, in adult patients with type 1 diabetes.
    Lecumberri E; Nattero-Chávez L; Quiñones Silva J; Alonso Díaz S; Fernández-Durán E; Dorado Avendaño B; Escobar-Morreale HF; Luque-Ramírez M
    Endocrine; 2022 Jun; 76(3):601-611. PubMed ID: 35349030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes.
    Riley DR; Hydes T; Hernadez G; Zhao SS; Alam U; Cuthbertson DJ
    Liver Int; 2024 Oct; 44(10):2538-2550. PubMed ID: 38949295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of metabolic dysfunction-associated steatotic liver disease in acute myocardial infarction: A propensity score-matched analysis.
    Kong G; Cao G; Koh J; Chan SP; Zhang A; Wong E; Chong B; Jauhari SM; Wang JW; Mehta A; Figtree GA; Mamas MA; Ng G; Chan KH; Chai P; Low AF; Lee CH; Yeo TC; Yip J; Foo R; Tan HC; Huang DQ; Muthiah M; Chan MY; Loh PH; Chew NWS
    Diabetes Obes Metab; 2024 Aug; 26(8):3328-3338. PubMed ID: 38779875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
    Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
    Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
    Stefan N; Hartleb M; Popovic B; Varona R
    Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants.
    Bril F; Kalavalapalli S; Lomonaco R; Frye R; Godinez Leiva E; Cusi K
    JHEP Rep; 2024 Jul; 6(7):101092. PubMed ID: 39022386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Wong RJ; Yang Z; Yeoh A; Do A; Ahmed A; Cheung R
    Am J Gastroenterol; 2024 Apr; ():. PubMed ID: 38477465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between antibiotic use and cardiovascular diseases in metabolic dysfunction-associated steatotic liver disease: A nationally representative retrospective cohort study.
    Kang JH; Park SJ; Jeong S; Park YJ; Kim HJ; Song J; Choi J; Park S; Kim J; Lee H; Chang J; Son JS; Park SM
    Hepatol Res; 2024 Sep; ():. PubMed ID: 39345177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
    Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
    Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term influence of type 2 diabetes and metabolic syndrome on all-cause and cardiovascular death, and microvascular and macrovascular complications in Chinese adults - A 30-year follow-up of the Da Qing diabetes study.
    He S; Wang J; Zhang X; Qian X; Yan S; Wang W; Zhang B; Chen X; An Y; Gong Q; Zhang L; Zhu X; Li H; Chen Y; Li G
    Diabetes Res Clin Pract; 2022 Sep; 191():110048. PubMed ID: 36029887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine Learning for Predicting Micro- and Macrovascular Complications in Individuals With Prediabetes or Diabetes: Retrospective Cohort Study.
    Schallmoser S; Zueger T; Kraus M; Saar-Tsechansky M; Stettler C; Feuerriegel S
    J Med Internet Res; 2023 Feb; 25():e42181. PubMed ID: 36848190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.